AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03948217 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Circadian Lighting regimen
Description: Circadian lighting regimen with one major fluctuation, high light intensity and color
Study NCT00867113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: imatinib mesylate was supplied in 100 and 400 mg tablets
Study NCT01970488 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Administered by subcutaneous injection
Study NCT01970488 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABP 501
Description: Administered by subcutaneous injection
Study NCT01795300 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Carbon Ion Radiotherapy
Description: Patients will be immobilized using an individually manufactured head mask for treatment planning and RT. Contrast-enhanced CT as well as MR-imaging will be performed for target volume definition. OAR such as the brain stem, optic nerves, chiasm and spinal chord will be contoured. The fractionation scheme will be taken into account for dose prescription, as well as DVH-characteristics and clinical parameters of the invidivual patient.~The Gross Tumor Volume (GTV) will be defined as the contrast-enhancing lesion on MRI on T1-weighted MR-imaging. Amino-Acid-PET or DOTATOC-PET may be used in addition to contrast-enhanced MRI for target volume definition but is not mandatory.The Clinical Target Volume (CTV) will be defined adding 1-2mm safety margin to the GTV.
Study NCT01795300 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Therapy
Description: As described previously, patients will be immobilized using an individually manufactured head mask for treatment planning and RT. Contrast-enhanced CT as well as MR-imaging will be performed for target volume definition. OAR such as the brain stem, optic nerves, chiasm and spinal chord will be contoured. Dose constraints of normal tissue will be respected according to Emami et al. (33). The fractionation scheme will be taken into account for dose prescription, as well as DVH-characteristics and clinical parameters of the invidivual patient.~The Gross Tumor Volume (GTV) will be defined as the contrast-enhancing lesion on MRI on T1-weighted MR-imaging. Amino-Acid-PET or DOTATOC-PET may be used in addition to contrast-enhanced MRI for target volume definition but is not mandatory.The Clinical Target Volume (CTV) will be defined adding 1-2mm safety margin to the GTV.
Study NCT01795300 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Photon Radiotherapy
Description: Treatment Planning for Photon Radiotherapy will be performed using the Planning Systems available at the Department of Radiation Oncology in Heidelberg, Germany (including Masterplan/Nucletron, Virtuos-Konrad/Siemens, or Precisis/STP/Stryker-Leibinger, or the Tomotherapy Software). Carbon ion and proton RT planning is performed using the treatment planning software PT-Planning (Siemens, Erlangen, Germany) including biologic plan optimization. Biologically effective dose distributions will be calculated using the a/ß ratio for meningioma as well as for the endpoint late toxicity to the brain. Patient positioning prior to radiotherapy will be evaluated by comparison of x-rays to the DRRs. Set up deviations >3mm are corrected prior to radiotherapy.~To the target volume defined for photon treatment, a total dose of 52.2 Gy E - 57.6 Gy E is applied in single fractions of 1.8Gy E. In the 3Gy E Photon arm, photon radiotherapy will be delivered to a total dose of 45 Gy E in 15 fractions.
Study NCT01795300 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Photon Radiotherapy
Description: Treatment Planning for Photon Radiotherapy will be performed using the Planning Systems available at the Department of Radiation Oncology in Heidelberg, Germany (including Masterplan/Nucletron, Virtuos-Konrad/Siemens, or Precisis/STP/Stryker-Leibinger, or the Tomotherapy Software). Carbon ion and proton RT planning is performed using the treatment planning software PT-Planning (Siemens, Erlangen, Germany) including biologic plan optimization. Biologically effective dose distributions will be calculated using the a/ß ratio for meningioma as well as for the endpoint late toxicity to the brain. Patient positioning prior to radiotherapy will be evaluated by comparison of x-rays to the DRRs. Set up deviations >3mm are corrected prior to radiotherapy.
Study NCT03326895 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left-sided colon resection
Description: Left-sided colon resection with powered stapler
Study NCT00364871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naltrexone and bupropion SR
Description: naltrexone 16, 32 or 48 mg/day and bupropion SR 400 mg/day
Study NCT00364871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naltrexone and bupropion SR
Description: naltrexone 16, 32 or 48 mg/day and bupropion SR 400 mg/day
Study NCT00364871 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: naltrexone and bupropion SR
Description: naltrexone 16, 32 or 48 mg/day and bupropion SR 400 mg/day
Study NCT04032769 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MODS (MOdified Diagnostic Strategy)
Description: Modified diagnostic strategy (MODS):~All included patients will be tested with quantitative D-dimer. The MODS work-up strategy will be based on YEARS rule, that included three criteria (hemoptysis, signs of DVT, PE is the most likely diagnosis)~- If all YEARS criteria are absent, the threshold of D-Dimer for ordering a CTPA will be raised at 1000 ng/ml.~If at least one criterion of YEARS is present, then the D-dimer threshold for ordering a CTPA will be as usual (500 ng/ml, or agex10 for patients aged 50 and over)
Study NCT03838354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Chidamide 2.5 mg po biw, every four weeks for one cycle. It will be given three cycles.
Study NCT03838354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Chidamide 5 mg po biw, every four weeks for one cycle. It will be given three cycles.
Study NCT04379336 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacille Calmette-Guérin (BCG)
Description: BCG vaccine will be given intradermally in the upper arm after randomization.
Study NCT04379336 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo injection will be given intradermally in the upper arm after randomization.
Study NCT02177890 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous vagal nerve stimulation
Study NCT02177890 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham vagal nerve stimulation
Study NCT04393025 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Intracranial Stenting by Intracranial Stent Device
Description: Large Intracranial Vessels with ICSD underwent catheter lab and IC stent is inserted
Study NCT04393025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimum medical treatment
Description: Optimum Medical treatment
Study NCT03178708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group A amantadine sulfate
Description: infusion solution for slowly intravenous application 3 hours preoperative
Study NCT03178708 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Group B ringer lactate
Description: infusion solution for intravenous application 3 hours preoperative
Study NCT04347850 — intervention group
Intervention type: OTHER
Intervention: blood sample
Description: Collection
Study NCT02068365 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pegyinterferon-alfa-2a
Description: Pegyinterferon-alfa-2a 180mcq weekly for 48 weeks
Study NCT00409253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: URAPIDIL (EUPRESSYL*)
Description: Urapidil (Eupressyl\*) :IV (PSE) 1 microg/kg/min° until reduction PAM 15 %. Reduction ¼ of the posology to obtain PAM between 105 and 125 mmHg with adjustment 0.25 microg/kg/min/15 min. Maximal dose = 30mg/h.
Study NCT00409253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NICARDIPINE
Description: Nicardipine : IV 6.25 mg bolus until PAD >105 mm/Hg. Perfusion (PSE) 4 mg/h to obtain PAM between 105 and 125 mm/Hg with adjustment 2mg/h/5 min without overshoot 20 mg/h Maximal treatment duration : 7 days
Study NCT01188473 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NPPV plus standard of care
Description: Patients in the NPPV group were fitted with a nasal mask with gel seals (Comfortgel Masks, Respironics) and placed on the BiPAP Machine (Vision Bipap, Respironics). To optimize patient cooperation, the mask was initially applied manually to the patient's face. After a short adaptation period, it was firmly applied on the face by head straps to minimize air leak without causing skin injury. Pressures were initially set low for comfort and acceptance while being placed on the machine. The inspiratory positive airway pressure (IPAP) was gradually increased to 8 cm H2O in order to achieve a tidal volume of 6-9 ml/kg and the end expiratory positive airway pressure (EPAP) to 5 cm H 2O. These settings remained unchanged throughout the study period.
Study NCT05044026 — intervention group
Intervention type: OTHER
Intervention: Jakavi
Description: Prospective observational study. There is no treatment allocation. Patients administered Jakavi by prescription and administered according to the SmPC.
Study NCT01287364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ciclesonide hydrofluoroalkane (HFA) nasal aerosol
Description: ciclesonide hydrofluoroalkane (HFA) nasal aerosol 80 μg once daily for one week.
Study NCT01287364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ciclesonide hydrofluoroalkane (HFA) nasal aerosol
Description: ciclesonide hydrofluoroalkane (HFA) nasal aerosol 80 μg once daily for one week.
Study NCT01287364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mometasone nasal inhalation
Description: mometasone nasal inhalation 200 μg once daily for one week
Study NCT01287364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mometasone nasal inhalation
Description: mometasone nasal inhalation 200 μg once daily for one week
Study NCT00593749 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Corner Store Initiative
Description: modification of snacks and beverages offered in corner store surrounding 10 schools
Study NCT00593749 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: control group in study
Study NCT04092062 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ToothWave
Description: RF-utilizing powered toothbrush for teeth whitening
Study NCT04092062 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: powered toothbrush
Description: regular powered toothbrush with no RF
Study NCT01603082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: 180 mg loading dose
Study NCT01603082 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 600 mg loading dose
Study NCT03570853 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART-3RP
Description: This is an 8-week, multimodal resiliency program that targets stress with 4 main components: mind-body skills (participants learn a variety of meditation techniques, mini relaxations, walking meditation, and yoga), traditional stress management techniques, healthy lifestyle behaviors (sleep, exercise, nutrition, and social support), and cognitive reappraisal and adaptive coping skills (borrowed from cognitive behavioral therapy, acceptance and commitment therapy, and positive psychology). The program consists of 8, 1.5 hour sessions.
Study NCT02616523 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: The participants will be given infusion of dexmedetomidine 0,5 mcg/kg/h intravenously.
Study NCT02616523 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: The participants will be given infusion of lidocaine 1,5 mg/kg/h intravenously.
Study NCT02616523 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The participants will be given infusion of normal saline intravenously.
Study NCT02616523 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl 2 mcg/kg will be given to all participants for the intubation and during the operation when ANI value drops below 50.
Study NCT02616523 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl 2 mcg/kg will be given to all participants for the intubation and during the operation when ANI value drops below 50.
Study NCT04359251 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gas exchanges at different PEEP
Description: Gas exchanges measurement at different PEEP
Study NCT04359251 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lung mechanics at different PEEP
Description: lung mechanics measurement at different PEEP
Study NCT04359251 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hemodynamics changes at different PEEP
Description: Hemodynamics changes measurement at different PEEP
Study NCT02187809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobazam
Study NCT03347721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine gel
Description: 2% lidocaine jelly, injected into the urethra
Study NCT03037619 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: Participants randomized to Fitbit will be mailed a Fitbit and encouraged to wear it over the next 4 months
Study NCT03037619 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitbit+Support
Description: Participants will identify a Buddy and both the participant and Buddy will be mailed a Fitbit. Both participant and Buddy will be asked to Friend each other on Fitbit and encouraged to wear the monitor over the next 4 months.
Study NCT01641809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 10 mg
Description: GSK1265744 10 mg will be administered orally once daily in combination with investigator-selected background NRTIs in the Induction Phase of the study and in combination with Rilpivirine 25 mg in the Maintenance Phase of the study.
Study NCT01641809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 30 mg
Description: GSK1265744 30 mg will be administered orally once daily in combination with investigator-selected background NRTIs in the Induction Phase of the study and in combination with Rilpivirine 25 mg in the Maintenance Phase of the study.
Study NCT01641809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 60 mg
Description: GSK1265744 60 mg will be administered orally once daily in combination with investigator-selected background NRTIs in the Induction Phase of the study and in combination with Rilpivirine 25 mg in the Maintenance Phase of the study.
Study NCT01641809 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz 600 mg
Description: Efavirenz 600 mg will be administered orally once daily in combination with investigator-selected background NRTIs in the Induction Phase and Maintenance Phase of the study.
Study NCT01641809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine 25 mg
Description: Rilpivirine 25 mg will be administered orally once daily in combination with GSK1265744 10 mg, 30 mg and 60 mg in the Maintenance Phase of the study.
Study NCT01641809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching to GSK1265744 will be administered along with GSK1265744 10 mg and 30 mg in the Induction phase and Maintenance phase of the study.
Study NCT01641809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC)
Description: The background dual NRTI therapy for all arms in the Induction Phase and Efavirenz 600 mg arm in the Maintenance Phase will be either abacavir 600 mg + lamivudine 300 mg (ABC/3TC) or tenofovir 300 mg + emtricitabine 200 mg (TDF/FTC) as selected by the Investigator.
Study NCT01641809 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC)
Description: The background dual NRTI therapy for all arms in the Induction Phase and Efavirenz 600 mg arm in the Maintenance Phase will be either abacavir 600 mg + lamivudine 300 mg (ABC/3TC) or tenofovir 300 mg + emtricitabine 200 mg (TDF/FTC) as selected by the Investigator.
Study NCT02329665 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeedleWays™ System
Description: A total of 50 consecutive subjects scheduled for clinically indicated CT guided needle intervention procedure will be invited to enroll in the study.
Study NCT03030235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10Mg Oral Tablet
Description: Dapagliflozin 10Mg Oral Tablet
Study NCT03347721 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lubricant Gel
Description: Lubricating gel
Study NCT04495244 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Syantra DX Breast Cancer
Description: Blood test for detecting the presence of breast cancer.
Study NCT03030235 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dapagliflozin matching placebo
Description: Dapagliflozin matching placebo
Study NCT02941133 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neural Mobilization
Description: Neural mobilization techniques aimed at the lumbar root that is affected
Study NCT02941133 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: Ultrasound - Transcutaneous electrical nerve stimulation (TENS) - Massage therapy - Strengthening exercises
Study NCT00443638 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nurse home visitation
Description: Nurse home visitation
Study NCT04932538 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kİnesio Taping
Description: Kinesio Taping® (KT) is used for pediatric rehabilitation to reduce pain, facilitate or inhibit muscle activity, prevent injuries, reposition joints, aid the lymphatic system, support postural alignment, and improve proprioception
Study NCT03193489 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-up
Study NCT03193489 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-treatment control
Description: After 3 weeks of intensive treatment, no special exercises are performed as a control.
Study NCT03193489 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Parkinson group
Description: No treatment.
Study NCT01050686 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: insertion of subcutaneous wound drain
Description: after the abdominal fascia is closed and before skin closure, a subcutaneous wound drain is inserted
Study NCT01050686 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: no insertion of subcutaneous wound drain
Description: closure of abdominal wall and skin without insertion of subcutaneous wound drain
Study NCT02927587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The induction Cet of propofol
Description: The induction Cet of propofol was targeted respectively at 1 and 2 ug/ml.
Study NCT02927587 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: The induction Cet of propofol
Description: The induction Cet of propofol was targeted respectively at 1 and 2 ug/ml.
Study NCT04646070 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Reduction mammaplasty
Description: Breast reduction surgery
Study NCT02366013 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rcAd26.MOS1.HIV-Env 1x10^8 vp
Description: 1 oral capsule, 1x10\^8 vp/capsule or 1 placebo capsule; 5:1 vaccine:placebo
Study NCT02366013 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rcAd26.MOS1.HIV-Env 1x10^9 vp
Description: 10 oral capsules, 1x10\^8 vp/capsule or 10 placebo capsules; 5:1 vaccine:placebo
Study NCT02366013 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rcAd26.MOS1.HIV-Env 1x10^10 vp
Description: 1 oral capsule, 1x10\^10 vp/capsule or 1 placebo capsule; 5:1 vaccine:placebo
Study NCT02366013 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rcAd26.MOS1.HIV-Env 1x10^11 vp
Description: 10 oral capsules, 1x10\^10 vp/capsule or 10 placebo capsules; 5:1 vaccine:placebo
Study NCT04669977 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mulberry juice
Description: One bottle (600ml/bottle) of sanitized mulberry juice would be sent to participants of the auxiliary group with instructions to consume 50ml of juice diluted with drinking water at room temperature. Also, a reminder of the next clinical visit is attached. They are expected to finish the mulberry juice in 10 to 11days instead of 12 days.
Study NCT01717768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSX-002
Description: TSX-002 are capsules with testosterone as the active ingredient.
Study NCT03750383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-938
Description: Subjects will receive EDP-938 once daily on Day 1 and Day 5 (Part 1)
Study NCT03750383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-938
Description: Subjects will receive one dose of EDP-938 on Day 1 and Day 8 (Part 2)
Study NCT03750383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Subjects will receive one dose of cyclosporine on Day 5
Study NCT03750383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Subjects will receive prednisone once daily from Day 5 to Day 14